--> THE CUNNINGHAM PANEL™ - Autoantibody testing for neuropsychiatric symptoms | R.E.D. Laboratories - Blog

$type=slider$sn=0$l=0$au=0$cm=0$show=home

THE CUNNINGHAM PANEL™ - Autoantibody testing for neuropsychiatric symptoms

There is a growing body of scientific evidence documenting the connection between infection, inflammation, immune dysfunction and the development of neurologic and psychiatric illnesses.

The Cunningham Panel™ helps clinicians identify whether a patient’s neurologic and/or psychiatric symptoms may be due to an infection-triggered basal ganglia encephalitis (BGE), which includes autoimmune neuropsychiatric syndromes such as PANS/PANDAS. Symptoms of BGE can mimic various mental illnesses.

The Cunningham Panel measures circulating levels of autoantibodies attacking brain receptors, as well as autoantibodies that stimulate the production of neurotransmitters in the basal ganglia. These interactions have the potential to disrupt neuronal functioning and can impact movement, behaviour and cognition. These test results can support a physician’s clinical diagnosis with laboratory evidence of an underlying autoimmune dysfunction, and assist the physician in determining an appropriate treatment regimen.

The Cunningham Panel™ is a metabolic test, the laboratory results represent the values at the time the patient’s blood was collected, which may vary over time, with treatment, and in conjunction with the presence or absence of symptoms. This panel is composed of 5 tests: Anti-Dopamine D1 Receptor, Anti-Dopamine D2L Receptor, Anti-Lysoganglioside-GM1, Anti-Tubulin and Calcium/calmodulin-dependent protein kinase II (CaMKII). First four of the tests measure the levels of circulating autoantibodies in serum that are directed against and bind to, or block specific neuronal targets in the brain. Each of these autoantibody targets (Dopamine D1 and D2L receptors,

Lysoganglioside-GM1 and Tubulin) have been associated with the presence of various neurologic and/or psychiatric symptoms. The last one, the CaMKII test is a cell stimulation assay. It measures the ability of a patient’s autoantibodies to stimulate the CaMKII enzyme in human brain cells. The CaMKII is involved in upregulating the production of neurotransmitters – dopamine, epinephrine, and norepinephrine and elevated levels of CaMKII activity correlated with certain adrenergic symptoms (these include nerve cells in which certain neurotransmitters activate), as well as the likelihood of an active infection or reinfection.

When autoantibodies bind to or block these targets, they can disrupt normal neuronal functioning, resulting in the onset of neuropsychiatric symptoms. Elevated levels on one or more of these tests indicate that a person’s neuropsychiatric symptoms may be due to a treatable autoimmune disorder (triggered by an infection(s), rather than a classic neurologic or psychiatric illness.

A link to the list of peer-reviewed journal articles by world-renowned researchers and clinicians investigating infection-induced autoimmune neurologic disorders.
 
The Cunningham Panel™ is unique and based on over two decades of research. It is offered exclusively through Moleculera Labs, Inc. and has been utilized by clinicians worldwide.

For European customers (outside UK, Ireland, Poland, Ukraine) this unique test is now available through R.E.D. Laboratories.

Please contact us at info@redlabs.be for further details and/or to order the kit. Moleculera Labs offers a wide range of training material and personalized guidance for practitioners.


$show=/p/events.html$type=two$m=0$rm=0$sn=0$c=10$p=1

$show=/p/faq.html$type=list$m=0$c=20$p=1

[STAFF PICK]_$type=sticky$h=318$c=4$h=318$l=0$icon=1$m=0$show=/p/faq.html

$show=/p/news.html$type=three$au=0$cm=0$c=9$p=1

[NEWS]_$type=blogging$l=0$c=5$au=0$cm=0$show=home

[STAFF PICK]_$type=sticky$h=318$c=4$h=318$l=0$icon=1$m=0$show=post

Name

events,33,faq,8,news,70,newsletter,9,staff pick,5,
ltr
item
R.E.D. Laboratories - Blog: THE CUNNINGHAM PANEL™ - Autoantibody testing for neuropsychiatric symptoms
THE CUNNINGHAM PANEL™ - Autoantibody testing for neuropsychiatric symptoms
https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgv1B0_FoYXGDGGpG-06-pObNXl3PQDgv__s8YPaei6LRlWFO_E99RIBhjkcAl2lBIWE1ZdqOEMk1HSRwA2f8gO651_CwHZFLiFbTBPswYOWbTBGr9CqQOOqJhLm45XStwgACKGVj1L-fPjOTuGLTJgfw_IVRq-3LLHaI73wwiHxyfgZTsBrnYaUPIMvw/w245-h174/What%20Does%20The%20Cunningham%20Panel%20Measure.jpg
https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgv1B0_FoYXGDGGpG-06-pObNXl3PQDgv__s8YPaei6LRlWFO_E99RIBhjkcAl2lBIWE1ZdqOEMk1HSRwA2f8gO651_CwHZFLiFbTBPswYOWbTBGr9CqQOOqJhLm45XStwgACKGVj1L-fPjOTuGLTJgfw_IVRq-3LLHaI73wwiHxyfgZTsBrnYaUPIMvw/s72-w245-c-h174/What%20Does%20The%20Cunningham%20Panel%20Measure.jpg
R.E.D. Laboratories - Blog
http://blog.redlaboratories.be/2022/10/the-cunningham-panel-autoantibody.html
http://blog.redlaboratories.be/
http://blog.redlaboratories.be/
http://blog.redlaboratories.be/2022/10/the-cunningham-panel-autoantibody.html
true
364229435959923836
UTF-8
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS PREMIUM CONTENT IS LOCKED STEP 1: Share. STEP 2: Click the link you shared to unlock Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy